20th Annual Conference
Nov 7-8, 2019
The Charles Hotel, Cambridge, MA
Spotlight Speakers
Lisa Alderson is the Co-Founder and CEO of Genome Medical, Inc., a leading telegenomics technology and services company that is dedicated to bringing genomics to everyday care. Through its nationwide network of genetic specialists and efficient genomic care delivery platform, Genome Medical provides health expertise throughout the genomics journey.Prior, Ms. Alderson served as the Chief Commercial Officer and Chief Strategy Officer of Invitae (NYSE: NVTA), a rapidly growing genetic information company. She was also the former CEO and president of CrossLoop Inc., a marketplace for technical services (acquired by Nasdaq: AVG). Prior to that, she was part of the start-up team at Genomic Health Inc. (Nasdaq: GHDX), president of Cinema Circle Inc., (acquired by Nasdaq: GAIA) and the former manager of strategic planning at The Walt Disney Co. Lisa is also a board member and advisor with a track record of creating, funding and managing high-growth ventures. She has an MBA with distinction from Harvard Business School and a B.A. from Colorado State University, where she graduated Summa Cum Laude.
Simon Bachleda (Co-Founder and Managing Partner). Mr. Bachleda has 19 years as an investment banking (2) and private equity professional (17). Since its founding, Revelstoke has raised $1.4 billion to invest in healthcare services companies. Prior to forming Revelstoke, Mr. Bachleda was a Managing Director of Eos Management, L.P., a New York City based private investment firm, and served as a General Partner of Eos’ 2004 vintage $325 million and 2007 vintage $600 million private equity funds. Prior to Eos, Mr. Bachleda was a private equity investment professional with KRG Capital Partners, a Denver-based private equity firm. Mr. Bachleda has sourced, led or is actively involved in over 70 private equity middle-market transactions, including over 20 platform company build-ups/consolidations and over 50 add-on investments. Mr. Bachleda is responsible for firm management, fundraising, investment professional development and execution and leadership of Revelstoke’s investment and value creation processes. Mr. Bachleda began his career as an investment banker in the mergers and acquisitions group of Credit Suisse First Boston, based in New York City. Mr. Bachleda serves on the board of directors of Fast Pace Urgent Care, Upstream Rehabilitation and Crossroads Treatment Centers. Mr. Bachleda was a former director of Rehab Services Corp, Addus Healthcare (NASDAQ: ADUS), BeavEx, Accelecare Wound Centers and Career Step and served as Chairman of the Board and Chairman of Nominating and Governance, Compliance, Compensation, Audit and Restructuring committees for publicly-traded and private companies. Mr. Bachleda is on the advisory board of the Burridge Center for Finance at the University of Colorado at Boulder. Mr. Bachleda has a B.S. in Business Administration from the University of Colorado at Boulder and an M.B.A from Harvard Business School.
Glenn Cohen is one of the world's leading experts on the intersection of bioethics (sometimes also called "medical ethics") and the law, as well as health law. His work has appeared in or been covered on PBS, NPR, ABC, CNN, MSNBC, Mother Jones, the New York Times, the New Republic, the Boston Globe, and several other media venues. He was the youngest professor on the faculty at Harvard Law School (tenured or untenured) both when he joined the faculty in 2008 (at age 29) and when he was tenured as a full professor in 2013 (at age 34), though not the youngest in history. He is the author of more than 100 articles and chapters and his award-winning work has appeared in leading legal (including the Stanford, Cornell, and Southern California Law Reviews), medical (including the New England Journal of Medicine, JAMA), bioethics (including the American Journal of Bioethics, the Hastings Center Report), scientific (Science, Cell, Nature Reviews Genetics) and public health (the American Journal of Public Health) journals, as well as Op-Eds in the New York Times and Washington Post. He is the author, co-author, editor, or co-editor of 12 books. They include: Health Care Law and Ethics (Aspen, 2018); Big Data, Health Law, and Bioethics (Cambridge University Press, 2018); Specimen Science (MIT Press, 2017); Nudging Health: Health Law and Behavioral Economics (John Hopkins University Press, 2016) The Oxford Handbook of U.S. Health Care Law (Oxford University Press, 2016); FDA in the Twenty-First Century: The Challenges of Regulating Drugs and New Technologies (Columbia University Press, 2015); Identified Versus Statistical Lives: An Interdisciplinary Perspective (Oxford University Press, 2015); Patients with Passports: Medical Tourism, Law, and Ethics (Oxford University Press, 2014); Human Subjects Research Regulation: Perspectives on the Future (MIT Press, 2014); The Globalization of Health Care: Legal and Ethical Issues (Oxford University Press, 2013).
Amy C. Edmondson is the Novartis Professor of Leadership and Management at the Harvard Business School, a chair established to support the study of human interactions that lead to the creation of successful enterprises that contribute to the betterment of society. Edmondson has been recognized by the biannual Thinkers50 global ranking of management thinkers in 2011, 2013, 2015 and 2017 and was honored with the Talent Award in 2017. She studies teaming, psychological safety, and leadership, and her articles have been published numerous academic and management outlets, including Administrative Science Quarterly, Academy of Management Journal, Harvard Business Review and California Management Review. Her books – Teaming: How organizations learn, innovate and compete in the knowledge economy (Jossey-Bass, 2012), Teaming to Innovate (Jossey-Bass, 2013) and Extreme Teaming (Emerald, 2017) – explore teamwork in dynamic organizational environments. In Building the future: Big teaming for audacious innovation (Berrett-Koehler, 2016), she examines the challenges and opportunities of teaming across industries to build smart cities. Her new book,The Fearless Organization: Creating Psychological Safety in the Workplace for Learning, Innovation and Growth (Wiley, 2018), offers a practical guide for organizations serious about success in the modern economy. Before her academic career, she was Director of Research at Pecos River Learning Centers, where she worked on transformational change in large companies. In the early 1980s, she worked as Chief Engineer for architect/inventor Buckminster Fuller, and her book A Fuller Explanation: The Synergetic Geometry of R. Buckminster Fuller (Birkauser Boston, 1987) clarifies Fuller's mathematical contributions for a non-technical audience. Edmondson received her PhD in organizational behavior, AM in psychology, and AB in engineering and design from Harvard University.
Neena Paul is the Chief Innovation Officer and Board Member at ?What If!. As a member of the board and global leadership team, Neena leads the development of our next generation products and services, infusing the mindsets and behaviors of experimentation into our own organization as well as our clients. Previously the U.S. CEO of ?What If!, Neena combines her experience leading and growing our business with her passion for partnering with other leaders to create a new future for their own organizations. She blends a problem obsession with real world, actionable solutions transforming organizations from the inside out. She created and incubated a digital wellness business helping to chart the company’s future by capturing a new customer demographic. By engineering a culture of innovation and experimentation across an organization, she helped ensure a financial services company remain a leader when the market gets disrupted.
Tina Ripperger is a Partner and the Global Head of Healthcare for ?What if!.Tina partners with ?What If!’s clients to embrace future forces to solve the real, human problems people face as they manage their health and wellness. She brings extensive sector experience to lead a diverse range of projects from growth strategy and business model innovation to reimagining the customer experience. Tina’s work has spanned countless therapy areas and clients within the health ecosystem, including: pharmaceutical manufacturers, provider organizations, health plans, patient advocacy groups, pharmacy benefit managers and retail/mail order/specialty pharmacies.
Julie Rubinstein is the President of Adaptive Biotechnologies. Ms. Rubinstein joined Adaptive in 2011 as the head of Corporate and Business Development. In 2016, she became the Chief Business Officer and led the company’s Life Sciences Research Business through two years of double-digit growth. Then, in February 2018, she began serving as President, overseeing the expansion of all of the business lines including Life Sciences Research, Clinical Diagnostics, and Drug Discovery, with continued oversight of Corporate and Business Development functions. Prior to joining Adaptive, Ms. Rubinstein held various worldwide commercial development roles at Pfizer Oncology, primarily focusing on cancer immunotherapy. She also held multiple positions at Johnson & Johnson’s Ethicon Endo-Surgery division, where she helped commercialize a breast cancer diagnostic device in major European markets. She began her career in Morgan Stanley’s Global Health Care Group as a financial analyst. Ms. Rubinstein holds a dual degree, Summa Cum Laude and Phi Beta Kappa, from the University of Pennsylvania’s Undergraduate Wharton School and Annenberg School of Communications, with a minor in French. She also holds an MBA from Harvard Business School. She currently serves on the Board of Trustees for The Valerie Fund, a pediatric oncology organization in New Jersey and New York.
Peter Stein, M.D., is the Director of CDER’s Office of New Drugs (OND). OND is responsible for the regulatory oversight of investigational studies during drug development and decisions regarding marketing approval for new (innovator or non-generic) drugs, including decisions related to changes to already marketed products. OND provides guidance to regulated industry on a wide variety of clinical, scientific, and regulatory matters. A nationally recognized leader in pharmaceutical research and development, Dr. Stein joined CDER in 2016 as the OND Deputy Director. Before coming to FDA, he served as Vice President for late stage development, diabetes, and endocrinology at Merck Research Laboratories. He also served as Vice President, head of metabolism development at Janssen. He has more than 30 years of academic, clinical, and industry experience. Dr. Stein holds a bachelor’s degree in history from the University of Rochester in New York and a medical degree from University of Pennsylvania. He trained at Yale University and Yale-New Haven Hospital in internal medicine and in endocrinology and metabolism.
Paul Stoffels, MD, is Vice Chair of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. He is a visionary leader who inspires and drives transformational innovation to bring years of life and quality of life to millions of people around the world. Paul spearheads the Johnson & Johnson research and product pipeline by leading teams across all our sectors to set the company-wide innovation agenda, discovering and developing transformational healthcare solutions. He also is responsible for the safety of all products of the Johnson & Johnson Family of Companies worldwide, and steers the company’s global public health strategy to make innovative medicines and technologies accessible in the world’s most vulnerable communities and resource-poor settings. Paul’s commitment to fueling innovation and finding the best science, wherever it exists, is the driving force behind the launch of Johnson & Johnson Innovation in 2013, which he now leads to foster science and technology through strategic partnerships, licensing and acquisitions. Paul also oversees JJDC, the oldest corporate venture fund in the life science industry. Previously, in his role as Worldwide Chairman, Pharmaceuticals, Paul led the transformation of the pharmaceutical research and development pipeline for Janssen Pharmaceutical Companies of Johnson & Johnson, driving a fundamental shift in the R&D paradigm that is now a model in the industry for productivity and innovation. Under his leadership, Janssen rejuvenated its pipeline, launching multiple new medicines and making a difference for people all over the world. Prior to this, Paul held various R&D leadership roles within the pharmaceutical sector of Johnson & Johnson. He joined Johnson & Johnson in 2002 with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and Chairman of Tibotec, and led the development of several breakthrough products for the treatment of HIV that helped to transform this devastating disease from a death sentence to a chronic and treatable condition. Paul studied Medicine at the University of Diepenbeek and the University of Antwerp in Belgium and Infectious Diseases and Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium. He began his career as a physician in Africa, focusing on HIV and tropical diseases research.
Distinguished Panelists
Rifat Atun is Professor of Global Health Systems at Harvard University and the Faculty Chair of the Harvard Ministerial Leadership Program. In 2008-12 he served as a member of the Executive Management Team of the Global Fund as Director of Strategy, Performance and Evaluation where he chaired the panel that oversaw annual investments of ~US$3-4 billion. In 2006-2013 he was a Professor of International Health Management at Imperial College London, where he led the Centre for Health Management and was involved as founder, adviser and investor in several biotech and health technology companies. He is a visiting professor at University of Kyoto, Japan. Professor Atun’s research focuses on health system transformation, and innovation. He has published over 300 papers in leading journals. Prof Atun has advised more than 30 governments on health policy and health system reform, and has worked with the World Bank, WHO and leading organizations such as Medtronic, Novartis, Roche, and Merck & Co.
Jonathan A. Epstein, M.D. graduated from Harvard College in 1983, Harvard Medical School in 1988 and completed his Residency and Fellowship in Medicine and Cardiology at the Brigham and Women's Hospital, where he also completed an HHMI Postdoctoral Fellowship in Genetics. In 1996 he accepted a position as Assistant Professor of Medicine in the Division of Cardiology at the University of Pennsylvania. From 2006-2015, he served as Chairman of the Department of Cell and Developmental Biology and Scientific Director of the Penn Cardiovascular Institute. He is currently the William Wikoff Smith Professor, Executive Vice Dean and Chief Scientific Officer at the Perelman School of Medicine at the University of Pennsylvania.Dr. Epstein has been the recipient of numerous awards, including the Sir William Osler Young Investigator Award from the Interurban Clinical Club (2001) and the Outstanding Investigator Award from the American Federation for Medical Research (2006). He is a member of the Philadelphia College of Physicians, American Academy of Arts and Sciences, American Association of Physicians, Past President of the Interurban Clinical Club, Past President of the American Society for Clinical Investigation and a member of the National Academy of Medicine (previously the Institute of Medicine). He serves on several editorial boards, and is a past Deputy Editor of the Journal of Clinical Investigation. Dr. Epstein was a founding co-director of the Penn Institute for Regenerative Medicine in 2007.Dr. Epstein’s research has focused on the molecular mechanisms of cardiovascular development and implications for understanding and treating human disease. His group has been at the forefront of utilizing animal models of congenital heart disease to determine genetic and molecular pathways required for cardiac morphogenesis, with implications for pediatric and adult cardiovascular disease. Stem cell, angiogenesis and epigenetic studies have had direct implications for the development of new therapeutic agents for heart failure and myocardial infarction.
Jeremy Goldberg, MBA ’89, is a skilled business development executive with over 25 years of experience, mainly focused on investing and business development in the pharmaceutical and healthcare industries. In addition to his work as Advisor at Torreya, he is an advisor to several funds focused on private equity and life sciences investments in the venture and royalty areas. He was a founding partner of ProQuest Investments in 1998, the first cancer-focused venture capital fund, where he and his partners raised over $250 million in Funds I and II to acquire positions in biotechnology, specialty pharmaceutical and medical device companies. Jeremy joined Endo Pharmaceuticals in 2003 as Managing Director, Corporate Development and was responsible for its overall corporate development activities, including structuring, negotiating and closing transactions. Jeremy’s transaction experience includes over 12 product licenses and multi-product license or acquisitions with U.S. and European companies announced while at Endo Pharmaceuticals. Prior operating experience includes roles as founding CEO or founder of three biotechnology companies that were acquired or taken public, including Versicor (Vicuron), a Sepracor spin-out later acquired by Pfizer, and operating roles at SmithKline and Becton Dickinson. He serves on the Dana Farber Cancer Institute Lank Center Visiting Committee and an NIH-Oxford affiliated board. Jeremy received his A.B. from Harvard College and M.B.A from Harvard Business School.
Ting Guo is the Head of Operations and Partnerships of Penguin Pay, a technology-driven social impact business that matches patients with prescription affordability options to increase adherence. Our initial product is an instant, 0% APR loan to help patients in need who do not qualify for assistance programs afford their medication. Through our data-driven eligibility process, we are also able to identify and qualify patients for copay assistance, PAPs and foundations. Prior to Penguin Pay, Ting co-founded Emmy, a health-tech startup that provided on-demand medical escorts to accompany patients to and from their ambulatory procedures. Ting also spent time as a consultant at Bain & Company, as an investment associate at a biotech venture firm, and as a healthcare analyst at BrightWire. She is passionate about and has spent time supporting social justice and economic empowerment organizations including Hagar International and America Needs You. Ting holds an MBA from Columbia Business School and a BA from Columbia University (Columbia College).
Paula M. Henderson, M.B.A., is the Chief Human Resources Officer (CHRO) at University of Mississippi Medical Center (UMMC) which includes the health system, seven professional schools, and the research mission. In her CHRO role at Mississippi’s only academic medical center, Henderson provides strategic direction for human resources functions in support of UMMC’s mission and long-term strategic goals, as well as operational planning and support for all human resources functions, for greater than 10,000 employed faculty and staff and nearly 3,000 students. Prior to University of Mississippi Medical Center, Henderson was Vice President of Human Resources with the University of Maryland Medical System based in Baltimore and was responsible for approximately 46 percent of the system and more than 10,000 employees at the three institutions for which she had oversight: University of Maryland Medical Center (University and Midtown Campuses) and UM Rehabilitation & Orthopaedic Institute. She served as a strategic partner and internal consultant to executive and line management and provided strategic leadership and specialized human resources expertise to assist the three hospitals in achieving their strategic and operational objectives. Previously, Henderson held leadership roles in Development for the Sisters of Notre Dame de Namur in Maryland, Human Resources at GTE Government Systems Corp. in Massachusetts and at Macy’s, Inc. in Pennsylvania. She earned a B.A. in French/Business from West Virginia University, and an M.B.A. with a concentration in Human Resources Management from the Joseph M. Katz Graduate School of Business, University of Pittsburgh. She is a member of a number of professional organizations, including the Society for Human Resources Management (SHRM).
Tyler Jacks, PhD, is the Director of the Koch Institute for Integrative Cancer Research at MIT, the David H. Koch Professor of Biology,and an Investigator of the Howard Hughes Medical Institute. Over the course of his career at MIT, Dr.Jacks has pioneered the use of gene targeting technology to study cancer-associated genes and to construct models of many human cancer types, including cancers of the lung, brain,and ovary. His laboratory has made seminal contributions to the understanding of the effects of mutations of several common cancer-associated genes. This research has led to novel insights into tumor development, normal development and other cellular processes, as well as new strategies for cancer detection and treatment.Dr.Jacks has published more than 300 scientific papers. Dr.Jacks has served on the Board of Scientific Advisors of the National Cancer Institute, is the immediate past chair of the National Cancer Advisory Board, and served as co-chair of Vice President Biden’s Cancer Moonshot’s Blue Ribbon Panel. He is an advisor to several biotechnology and pharmaceutical companies, and is a member of the Board of Directors of Amgen and Thermo Fisher Scientific. He is a founder of T2 Biosciences and Dragonfly Therapeutics, where he serves as chair of the Scientific Advisory Board.Among many honors, Dr.Jacks is a member of the National Academy of Sciences,the National Academy of Medicine, the American Academy of Arts and Sciences, and the Fellows of the American Association of Cancer Research Academy.In 2015, he received the Killian Award, the highest honor MIT bestow upon a member of its faculty.
Josh Lerner graduated from Yale College with a special divisional major. He worked for several years on issues concerning technological innovation and public policy at the Brookings Institution, for a public-private task force in Chicago, and on Capitol Hill. He then earned a Ph.D. from Harvard's Economics Department. Much of his research focuses on venture capital and private equity organizations. (This research is collected in three books, The Venture Capital Cycle, The Money of Invention, and Boulevard of Broken Dreams.) He also examines policies on innovation and how they impact firm strategies. (That research is discussed in the books Innovation and Its Discontents, The Comingled Code, and The Architecture of Innovation.) He co-directs the National Bureau of Economic Research’s Productivity, Innovation, and Entrepreneurship Program and serves as co-editor of their publication, Innovation Policy and the Economy. He founded and runs the Private Capital Research Institute, a nonprofit devoted to encouraging access to data and research, and has been a frequent leader of and participant in the World Economic Forum projects and events. In the 1993-1994 academic year, he introduced an elective course for second-year MBAs. Over the past two decades, “Venture Capital and Private Equity” has consistently been one of the largest elective courses at Harvard Business School. (The course materials are collected in Venture Capital and Private Equity: A Casebook, now in its fifth edition, and the textbook Venture Capital, Private Equity, and the Financing of Entrepreneurship.) He also established and teaches doctoral courses on entrepreneurship, teaches in the Owners-Presidents-Managers Program, and leads executive courses on private equity. He is the Jacob H. Schiff Professor and Chair of the Entrepreneurial Management unit. Among other recognitions, he is the winner of the Swedish government’s Global Entrepreneurship Research Award and Cheng Siwei Award for Venture Capital Research. For information on Josh’s compensated outside activities, please see www.bella-pm.com.
Mathai Mammen, M.D., Ph.D. is the Global Head of R&D at the Janssen Pharmaceutical Companies of Johnson & Johnson. Mathai's mission is to focus the energy of the best research and development teams in the world at the intersection of profound unmet medical need and actionable breakthroughs in science and technology to make medicines of unequivocal benefit for humanity. The team works across a wide range of therapeutic areas and biological pathways. Janssen’s approach to medicines is patient-focused, agnostic to both source of the idea and the treatment modality. The team is invested deeply in data sciences in every aspect of R&D. Janssen R&D has fueled the growth of Janssen to be the largest pharmaceutical company in the United States, and the fourth largest in the world. Prior to Janssen, Mathai was SVP at Merck Research Laboratories, and with histeamhe initiated numerous new programs and progressed eight into early clinical development. At Theravance, a company he co-founded in 1997 based on his work at Harvard University, his talented team nominated 31 development candidates in 17 years, created four approved products,and filed for approval of a fifth. Mathai has more than 150 peer-reviewed publications and patents and serves on various boards and advisory committees. He received his M.D. from Harvard Medical School/Massachusetts Institute of Technology (HST program) and his Ph.D. in Chemistry from Harvard University's Department of Chemistry.
Kush Parmar, M.D., Ph.D., M.D., M.B.A., is a Managing Partner at 5AM Ventures. Dr. Parmar serves as a Director on the Boards of Akouos, Arvinas (NASDAQ: ARVN), Entrada, Homology (NASDAQ: FIXX), Rally Bio and Vor Biopharma. He previously served as Acting VP of Strategy and Corporate Development at Novira (acquired by J&J) and served as Board Member or Observer for Achaogen (NASDAQ: AKAO), Audentes (NASDAQ: BOLD), Envoy (acquired by Takeda) and scPharmaceuticals (NASDAQ: SCPH). Dr. Parmar serves on the Advisory Boards of Penn Medicine, Princeton University’s Department of Molecular Biology, and the Grace Science Foundation. He is a Fellow of the Society of Kauffman Fellows. Prior to 5AM, Dr. Parmar was at Harvard Medical School, where he was an NIH-sponsored M.D./Ph.D. Physician Scientist Fellow in the Harvard-MIT Health Sciences and Technology Program. He completed clinical clerkships at the Massachusetts General & Brigham and Women’s Hospitals. At Princeton University, Dr. Parmar worked on developmental genetics with Eric F. Wieschaus (Nobel Prize in Medicine in 1995). He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University and an M.D. from Harvard Medical School.
Michael S. Sherman, M.D., M.B.A., serves as Chief Medical Officer and Senior Vice President for Harvard Pilgrim Health Care Dr. Sherman and on the faculty of Harvard Medical School’s Department of Population Medicine. He has been a leader in driving adoption of outcomes-based provider and pharmaceutical contracts. Dr. Sherman holds a B.A. and an M.S. in biomedical anthropology from the University of Pennsylvania and received his M.D. from Yale and M.B.A. from the Harvard Business School.
Lesley Solomon became Dana-Farber’s senior vice president and chief innovation officer in 2017. She has served as the founding executive director of Brigham and Women’s Hospital's Innovation Hub, and as director of strategy and innovation in the Brigham Research Institute. Ms. Solomon has more than 20 years of experience as an executive working in business development, strategy, and marketing at startups, early-stage, and large companies such as the Food Network, Barnes & Noble.com, and Yoga Works. She received her MBA from Harvard Business School and has a BA in English from Cornell University. She is a co-founder of the Food Allergy Science Initiative at The Broad Institute of Harvard and MIT, which brings together experts across disciplines to unlock the biology of food allergy and change the field to develop new treatments and more.
Manu Tandon serves as the Chief Information Officer for Beth Israel Deaconess Medical Center, a Harvard Medical School affiliated Academic Medical Center. In his current role, he is responsible for all IT matters pertaining to the Academic Medical Center. He directs BIDMC's "Center for IT Exploration" which works to adopt innovative analytics, mobile, cloud and AI/ML solutions for operational efficiencies and to enhance the experience of BIDMC's providers, patients and staff. Before joining BIDMC in 2014, Manu served as the Secretariat CIO for Massachusetts Executive Office of Health and Human Services where he led the state’s largest IT public portfolio. As Massachusetts' state HIT Coordinator, Manu led the development of the nation's first medicaid funded statewide Health Information Exchange (HIE) known as "MassHIWay" which has now delivered over 200 Million healthcare transactions since its inception. Manu was recognized by Computer World as one of the top "100 Premier IT Leaders” in the world and by New England HIMSS as "The CIO of the Year" for 2014. Manu has an engineering degree from Indian Institute of Technology, an MBA from Boston University and an MPA from Harvard Kennedy School.